(Q33389446)

English

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

Rodney J. Hicks

object named as

Rodney John Hicks

6

0 references

author name string

Daniel Hubble

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Grace Kong

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Michael

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Val Johnson

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shakher Ramdave

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

6 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

37

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1869-1875

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s00259-010-1483-4

0 references

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy and biotherapy in neuroendocrine tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The nonuniformity of antibody distribution in the kidney and its influence on dosimetry

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Yttrium-90 DOTATOC: first clinical results

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumour biology and histopathology of neuroendocrine tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/20445977

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-010-1483-4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33389446&oldid=1802450747"